Keytruda

Roche’s Tecentriq yields positive data in early stage NSCLC

the dominant shadow of Merck &Co’s Keytruda (pembrolizumab). ... Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC.

NICE rejects Keytruda for advanced bladder cancer in final guidance

Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients. ... In a statement issued today, NICE said that although

FDA advisory committee to review oncology accelerated approvals

trials. However, continued approval in this indication was dependent on a post-marketing study demonstrating the superiority of Keytruda as determined by overall survival (OS). ... Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as

Novartis’ canakinumab misses the mark in previously treated NSCLC

The CANOPY-1 study, evaluating canakinumab in combination with Merck &Co’s Keytruda (pembrolizumab) and chemotherapy in previously untreated NSCLC patients, could report final results before the end of the year.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]